<DOC>
	<DOCNO>NCT01176474</DOCNO>
	<brief_summary>The purpose study test side effect investigational vaccine immune booster , 2 different booster together . Investigators also want find effect immune system whether decrease chance melanoma return .</brief_summary>
	<brief_title>Vaccine Combining Multiple Class I Peptides Montanide ISA 51VG With Escalating Doses Anti-PD-1 Antibody Nivolumab Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma</brief_title>
	<detailed_description>Up 5 dose cohort study . Participants assign dose cohort order enter study . - 1 mg/kg NIVOLUMAB + peptide vaccine ( 1 mg/kg cohort ) , - 3 mg/kg NIVOLUMAB + peptide vaccine ( 3 mg/kg cohort ) , - 10 mg/kg NIVOLUMAB + peptide vaccine ( 10 mg/kg cohort ) , - 1 mg/kg NIVOLUMAB + ipilimumab 3 mg/kg combination cohort - 3 mg/kg NIVOLUMAB + ipilimumab 1 mg/kg combination cohort</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Histologic diagnosis resect Stages IIIC/ IV melanoma , evidence disease clinically radiologically . All melanomas regardless primary site disease allow . HLAA*0201 positive determine deoxyribonucleic ( DNA ) allelespecific polymerase chain reaction ( PCR ) assay ; HLA restriction require cohort 4 Positive stain recently resect tumor tissue antibodies 1 following : human melanoma black 45 ( HMB 45 ) gp100 , NYESO1 , and/or MART1 Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Prior chemotherapy immunotherapy ( tumor vaccine , cytokine , growth factor give control cancer ) must complete least 4 week study drug administration , adverse event either return baseline stabilize . Prior treat brain meningeal metastasis must without magnetic resonance imaging ( MRI ) evidence progression least 8 week immunosuppressive dos systemic steroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week study drug administration . Prior systemic radiation therapy must complete least 4 week study drug administration . Prior focal radiotherapy complete least 2 week study drug administration . No radiopharmaceutical ( strontium , samarium ) within 8 week study drug administration . Immunosuppressive dos systemic medication , steroid absorb topical steroid ( dos &gt; 10 mg/day prednisone equivalent ) must discontinue least 2 week study drug administration . Completed nitrosourea treatment least 6 week administration study drug . Prior surgery require general anesthesia must complete least 4 week study drug administration . Surgery require local/epidural anesthesia must complete least 72 hour study drug administration participant recover . Screening laboratory value must meet following criterion : white blood cell ( WBCs ) ≥ 2000 cells/μL , neutrophil ≥ 1500 cells/μL , platelet ≥ 100 x 10^3/μL , hemoglobin ≥ 9.0 g/dL , serum creatinine ≤ 2 mg/dL , aspartic transaminase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) without , ≤ 5 x ULN hepatic metastasis , alanine transaminase ( ALT ) ≤ 2.5 x ULN without , ≤ 5 x ULN hepatic metastasis , bilirubin ≤ 2 x ULN ( except participant Gilbert 's syndrome , must total bilirubin &lt; 3.0 mg/dL ) . Females childbearing potential ( FOCBP ) must : Agree use use reliable form contraception ( e.g. , oral contraceptive , intrauterine device , double barrier method condom spermicidal ) least 28 day prior first dose study drug , Treatment Period ( Treatment/Followup receive study drug ) , least 70 day last dose study drug ; negative serum βhuman chorionic gonadotropin ( βHCG ) Screening . For female participant consider childbearing potential , must meet 1 follow criterion : postmenopausal least 24 consecutive month ; surgically sterile ( ie , hysterectomy bilateral oophorectomy ) ; females irregular menstrual period and/or hormone replacement therapy must document serum follicle stimulate hormone level &gt; 35 mIU/mL . Male participant must agree use male contraception Treatment Period least 180 day last dose study drug . Must read , understood , provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization nature study fully explain . Willing adhere study visit schedule prohibition restriction specify protocol . History severe hypersensitivity reaction monoclonal antibody ( mAbs ) . Systemic hypersensitivity Montanide ISA 51 VG vaccine component . Prior nonmelanoma malignancy active within previous 2 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix breast . Any active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except participant vitiligo resolve childhood asthma/atopy . Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . Positive test hepatitis B virus surface antigen ( HBV SAg ) hepatitis C virus ribonucleic acid ( HCV RNA ) indicate active chronic infection . Prior therapy antiProgrammed Death1 ( antiPD1 ) , antiProgrammed DeathLigand 1 ( antiPDL1 ) , antiprogrammed deathligand2 ( antiPDL2 ) , anticytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody ( antibody target T cell costimulation pathway ) . Concurrent medical condition require use immunosuppressive medication , immunosuppressive dos systemic absorbable topical corticosteroid . Underlying medical condition ( eg , condition associate diarrhea ) , Investigator 's opinion , would make administration either study drug study drug hazardous participant obscure interpretation toxicity determination adverse event . Pregnant nursing . Current participation another clinical study involve treatment medication , radiation surgery , prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>